Search

ASCO18: MIXED REACTION TO NEKTAR'S ‘CONFUSING' NKTR-214 TRIAL

Nektar Therapeutics' much-anticipated data from a study pairing its immuno-oncology prospect NKTR-214 with Bristol-Myers Squibb's checkpoint...

 
 
 
Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks

BIO ROUNDUP: CMS BACKS CANCER TESTS, RIGHT TO TRY PASSES, ABBVIE SINKS

We'll start this week's roundup with several stories from Washington, D.C. that could have a lasting effect on public health. The FDA...

BRISTOL-MYERS' LUNG CANCER OPDIVO-YERVOY COMBO WOWS IN PHASE III STUDY

Additionally, based on an interim analysis for overall survival , the Data Monitoring Committee recommended that the study continue

 
 
 
HIV breakthrough as cancer drug does wonders for patient

HIV BREAKTHROUGH AS CANCER DRUG DOES WONDERS FOR PATIENT

A 51-year old French man given nivolumab - sold as Opdivo - saw a 'drastic and persistent decrease' in the reservoirs of cells where...

INNATE TANKED AS DRUG COMBINED WITH BRISTOL-MYERS' OPDIVO FLOPPED IN STUDY

While lirilumab was shown to be well-tolerated, it did not provide clear evidence of benefit to patients or an obvious development...

 
 
 
Roche Gains Ground on Rivals With Drug Combo's Success in Lung Cancer

ROCHE GAINS GROUND ON RIVALS WITH DRUG COMBO'S SUCCESS IN LUNG CANCER

Roche/Genentech reported this morning that its cancer immunotherapy drug, atezolizumab , has succeeded in a clinical study that could...

 
 
 
 
 
 
 
 
 

BRISTOL-MYERS SQUIBB RELEASE: PHASE III STUDY EVALUATING THE SAFETY AND EFFICACY OF ADJUVANT OPDIVO IN RESECTED HIGH-RISK MELANOMA PATIENTS MEETS PRIMARY ENDPOINT

Life Sciences Jobs ...

 
 
 
Bristol-Myers beat on earnings thanks to sales of its drugs that use the immune system to treat cancer

BRISTOL-MYERS BEAT ON EARNINGS THANKS TO SALES OF ITS DRUGS THAT USE THE IMMUNE SYSTEM TO TREAT CANCER

Thomson Reuters NEW YORK - Bristol-Myers Squibb Co on Thursday posted better-than-expected first-quarter earnings, helped by growth...

A combination of cancer drugs works better than on their own - but there's a catch

A COMBINATION OF CANCER DRUGS WORKS BETTER THAN ON THEIR OWN - BUT THERE'S A CATCH

Shutterstock April 3 - Patients with advanced melanoma who received Bristol-Myers Squibb's immunotherapies Opdivo and Yervoy had improved...

 
 
 
First Trial Underway, CytomX Gets $200M More In Expanded Bristol Pact

FIRST TRIAL UNDERWAY, CYTOMX GETS $200M MORE IN EXPANDED BRISTOL PACT

It's tough to stand out in the cancer immunotherapy crowd, where a slew of companies are testing a variety of drug combinations and...